Also see: GM, Arch Coal: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
Automatic Data Processing
(ADP - Get Report)
price target was lifted at Citigroup to $59 from $54. In-line quarter and improved outlook, Citigroup said. Maintain Buy rating.
price target cut was at Citigroup to $23 from $28. Restructuring expenses pressure earnings, Citigroup said. Maintain Hold rating.
(APC - Get Report)
estimates were raised through 2012 at UBS. Company is seeing higher production rates, UBS. Buy rating and new $98 price target.
estimates, target cut were at Goldman Sachs. Warrants will dilute earnings, Goldman said. Neutral rating and new $9.50 price target.
(CE - Get Report)
price target was raised to $55 at Morgan Stanley. Estimates also increased, as Asia is driving growth, Morgan Stanley said. Overweight rating.
(CHK - Get Report)
estimates were reduced at UBS through 2012. Company is boosting its capital spending budget, UBS said. Neutral rating and $34 price target.
Corn Products International
price target were raised at Citigroup to $70 from $60. Better-than-expected first quarter is a strong start for 2011, and further upside revisions are possible, Citigroup said. Maintain Buy rating.
Corn Products International's price target boosted to $58 at Morgan Stanley. Estimates also raised, as the company is realizing better pricing power. Equal-weight rating.
estimates, price target were raised at Goldman Sachs. Shares now seen reaching $109, according to Goldman. Estimates also increased, given strong European agriculture demand. Neutral rating.
numbers were raised at UBS. Shares now seen reaching $33. Estimates also increased, following the resolution of the TIVO litigation. Neutral rating.
estimates were raised through 2013 at Morgan Stanley. Company boosted its guidance, Morgan Stanley said. Overweight rating and new $124 price target.
price target was increased at Citigroup to $26 from $24. Tomo intelligence indicates high probability of share capture, Citigroup said. Maintain Buy rating.
Hologic estimates were raised through 2013 at Goldman Sachs. Company boosted guidance, given better product adoption, Goldman said. Buy rating and new $26 price target.
numbers were raised at Goldman Sachs. Estimates were boosted through 2013, and company is leveraged to secular growth drivers, Goldman said. Neutral rating and new $34 price target.